U.S. markets close in 27 minutes

Synlogic, Inc. (SYBX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.3200-0.0100 (-0.30%)
As of 3:30PM EDT. Market open.
Sign in to post a message.
  • B
    Bruno
    JonesTrading analyst Lina Kaminski initiated coverage of Synlogic with a Buy rating and $15 price target. Kaminski sees "a unique buying opportunity" ahead of the release of proof of concept data readouts of SYNB1618 for phenylketonuria and SYNB8802 for enteric hyperoxaluria in mid-2021. Both data releases could potentially represent "major inflection points" for shares from current levels, Kaminski added.

    3/18/2021
  • E
    Eric M W
    --Analyst Actions: Jones Trading Starts Synlogic at Buy With $15 Price Target
    8:29 AM ET, 03/18/2021 - MT Newswires
    08:29 AM EDT, 03/18/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

    Price: 4.5500, Change: +0.37, Percent Change: +8.85
  • f
    fpdtls@
    SYBX .. bring on the luck of the IRISH!
  • C
    C. Craig
    This stock had a 95-97 rating on InvestorsObserver a week/ 10 days ago with heavy promotion as 'strong buy.' I bought the stock at $5.02. The next day the rating was 87, now it's 70. The stock has lost FORTY PERCENT of its value in a week! It's selling at $3.10 now. The selling was with large relative trades. Does anyone know where we can find out if there is INSIDER SELLING? They are due to report earnings or rather losses in a week. If there has been a lot of insider trading, it's time to get a lawyer and the SEC involved.
  • f
    fpdtls@
    Buying the dip and holding
    Bullish
  • t
    tom
    I think this is a great stock to get into biotech on the cheap with serious growth potential. They have been working on Synthetic Biotic medicines to treat rare gut disorders. This stuff probably won't be super lucrative, but they are laying the ground work for money medicines for treatments of diabetes and obesity. They also have a cancer drug in clinical trials for the treatment of tumors. If that trial goes well, I would expect a bump in the price. On the downside they are burning cash like it's going out of style, but that is to be expected for a relatively new company developing medicines that hasn't brought anything to market. It looks like a great management team, CEO, and Board, despite the lack of revenue. They seem to be controlling costs relative to other companies in this sector.

    The other thing I like about this company is the location and connections. They are in Cambridge, MA, close to major educational institutions that they need for talent and collaboration, e.g. they just partnered with MIT and won a 1m DOD grant to study battle fatigue (Chug Jug anyone?). They are also partnered with Gingko Bioworks, would love to own (not publicly traded), a cell programming company out of Boston that has a significant position in SYBX, 6.3m shares.

    Ram Selvaraju with H.C. Wainwright, an analyst with solid returns in this sector rates it a buy with a target price of $13.

    If you want a comparable at this price point, check out GNCA.

    Disclosure: I have a small position in SYBX and no position in GNCA.
    Bullish
  • f
    fpdtls@
    they are going to do big things!
    Bullish
  • B
    Bruno
    Chardan doubles Synlogic target to $10, names top 2021 pick

    Chardan analyst Gbola Amusa raised the firm's price target on Synlogic to $10 from $5 and keeps a Buy rating on the shares. Synlogic, trading at a 13% discount to cash, is not priced for the potential of its three "possible and different" clinical-stage readouts in 2021, Amusa tells investors in a research note. The analyst made the company a "Chardan Top Pick for 2021." Though the stock traded down on the failure of SYNB1020 in cirrhosis, that asset faced two issues: whether SYNB1020 can modulate a toxic metabolite, and whether modulating the toxic metabolite matters, says Amusa. For current Synlogic's metabolic assets, the biology is relatively well understood, so that only the first issue is a main controversy for 2021, the analyst adds. Amusa believes Synlogic has a "differentiated" genetically-engineered live biotherapeutic product platform to improve clinical outcomes in target areas of oncology and disorders of metabolism.
  • B
    Bruno
    Department of Defense

    Together, Synlogic and the Voigt Lab will collaborate to generate and manufacture engineered strains by performing an assessment of process manufacturability, with optimization performed to maximize high cell density growth and high end of fermentation (EOF) viability. The goal of this work is to produce a live bacterial therapeutic that would improve pilot performance and decision-making when battling fatigue during long missions.
  • C
    C. Craig
    Something must be bad with the earning coming out in two days if the stock is tumbling yesterday and today. Not good.
  • J
    Jason
    i can't decide whether the MMs are just cleaning out the weak habds and this is going to close higher, or the results were uninspiring and the price action reflects this fact. your guess is as good as mine!
  • T
    Trader Nick 44
    $SENS conversation
    I posted this before. $SENS, printing classic flag/pennant on the daily chart. I'm not going to go into the technical's of a flag/pennant pattern, look it up, if you're interested. If you're interested in seeing the resulting breakout, check out $SYBX, breaking out today. it's just a matter of time for $SENS. Volume will signal the breakout and is what's going to push this higher.
  • Y
    Yahoo Finance Insights
    Synlogic is down 10.12% to 4.44
  • T
    Trader Nick 44
    $SENS conversation
    $SENS, printing classic flag/pennant on the daily chart. If you're interested in seeing the resulting breakout, check out $SYBX, breaking out today. it's just a matter of time for $SENS.
  • K
    Kevin
    How is there no one here commenting on this recent runup?
  • J
    Jason
    looks like the after hours crowd isn't impressed with the PR. oh well.
  • Y
    Yahoo Finance Insights
    Synlogic is down 10.41% to 4.39
  • J
    Jason
    could be bad news at virtual conference today
  • S
    SloppyTots
    Excellent potential for blockbuster status on SYNB1618. May treat innumerable GI disorders as a carbon monoxide bioreactor. Very exciting prospect.
  • Y
    Yahoo Finance Insights
    Synlogic reached a 52 Week high at 5.00